6,210 Shares in Sanofi $SNY Bought by West Michigan Advisors LLC

West Michigan Advisors LLC bought a new position in shares of Sanofi (NASDAQ:SNY) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 6,210 shares of the company’s stock, valued at approximately $300,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its stake in Sanofi by 1.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,036,878 shares of the company’s stock worth $612,106,000 after purchasing an additional 193,196 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of Sanofi by 58.5% in the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock valued at $218,933,000 after acquiring an additional 1,456,269 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Sanofi by 6.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company’s stock valued at $181,764,000 after acquiring an additional 211,641 shares during the last quarter. Raymond James Financial Inc. increased its holdings in shares of Sanofi by 15.1% in the 1st quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock valued at $179,914,000 after acquiring an additional 425,597 shares during the last quarter. Finally, Nuveen LLC purchased a new position in shares of Sanofi in the 1st quarter valued at about $177,831,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a report on Wednesday, October 8th. Barclays reiterated an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Sanofi has a consensus rating of “Buy” and a consensus target price of $62.67.

Sanofi Stock Up 4.3%

Sanofi stock opened at $51.64 on Friday. The stock has a market capitalization of $126.80 billion, a price-to-earnings ratio of 12.41, a PEG ratio of 1.20 and a beta of 0.51. The stock has a 50 day moving average of $48.65 and a two-hundred day moving average of $49.55. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business’s quarterly revenue was down 7.0% on a year-over-year basis. During the same period last year, the company posted $1.73 earnings per share. As a group, research analysts expect that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.